Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Not Confirmed
Not Confirmed
18-20 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Industry Trade Show
Not Confirmed
18-20 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
11 Nov 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/agc-biologics-aims-become-safe-harbor-manufacturing-clients-new-ceo-takes-reins
28 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/935952/agc-biologics-appoints-alberto-santagostino-as-new-chief-executive-officer
17 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/932698/agc-biologics-seattle-achieves-approval-for-all-2024-biologics-license-applications-from-us-food-and-drug-administration-concluding-pre-license-inspection
10 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/929772/agc-biologics-begins-operations-at-new-state-of-the-art-manufacturing-building-in-copenhagen-after-successful-inspection-and-licensing-from-danish-medicines-agency
30 Sep 2024
// ACCESSWIRE
https://www.accesswire.com/908940/agc-biologics-strengthens-portfolio-with-latest-fda-commercial-approval-at-copenhagen-facility
24 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/agc-biologics-telegraphs-95-layoffs-idles-cell-gene-plant-amid-tough-cdmo-environment
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Registration Number : 304MF20003
Registrant's Address : Vandtaarnsvej 83B, DK-2860 Soeborg Copenhagen, Denmark
Initial Date of Registration : 2022-03-02
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Registration Number : 304MF20005
Registrant's Address : Vandtaarnsvej 83B, DK-2860 Soeborg Copenhagen, Denmark
Initial Date of Registration : 2022-03-02
Latest Date of Registration :
Details:
NEC Bio collaborate with AGC Biologics to support the manufacturing and development of NECVAX-NEO1, which is being evaluated in the early-stage for treatingf solid tumors.
Lead Product(s): NECVAX-NEO1
Therapeutic Area: Oncology Brand Name: NECVAX-NEO1
Study Phase: Phase IProduct Type: Vaccine
Recipient: NEC Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2024
Lead Product(s) : NECVAX-NEO1
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : NEC Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
NEC Bio Therapeutics and AGC Biologics Collaborate on Personalized Cancer Vaccines
Details : NEC Bio collaborate with AGC Biologics to support the manufacturing and development of NECVAX-NEO1, which is being evaluated in the early-stage for treatingf solid tumors.
Brand Name : NECVAX-NEO1
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 08, 2024
Details:
AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).
Lead Product(s): Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Hu14.18K322A
Study Phase: Phase IIProduct Type: Large molecule
Recipient: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 11, 2024
Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Essential Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma
Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).
Brand Name : Hu14.18K322A
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 11, 2024
Details:
Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
Lead Product(s): MDG1015,PD1-41BB
Therapeutic Area: Oncology Brand Name: MDG1015
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Medigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2023
Lead Product(s) : MDG1015,PD1-41BB
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Medigene
Deal Size : Undisclosed
Deal Type : Agreement
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
Details : Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
Brand Name : MDG1015
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 25, 2023
Details:
Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Cell and Gene therapy
Sponsor: The Jikei University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : The Jikei University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 03, 2023
Details:
Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.
Lead Product(s): Teplizumab-mzwv
Therapeutic Area: Endocrinology Brand Name: Tzield
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Provention Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Lead Product(s) : Teplizumab-mzwv
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Provention Bio
Deal Size : Undisclosed
Deal Type : Agreement
AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy
Details : Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.
Brand Name : Tzield
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 24, 2023
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP Peanut
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Vaccine
Recipient: Allergy Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : Allergy Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP-Based Peanut Allergy Vaccine
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Vaccine
Sponsor: Allergy Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Lead Product(s) : VLP-Based Peanut Allergy Vaccine
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Allergy Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Details:
AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine (BNT162b2) manufacturing process.
Lead Product(s): BNT162b2
Therapeutic Area: Infections and Infectious Diseases Brand Name: BNT162b2
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 07, 2021
Lead Product(s) : BNT162b2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Partnership
AGC Biologics Inks Supply Deal for COVID-19 Vaccine
Details : AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine (BNT162b2) manufacturing process.
Brand Name : BNT162b2
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 07, 2021
Details:
OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.
Lead Product(s): OCS-02
Therapeutic Area: Ophthalmology Brand Name: OCS-02
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Oculis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 06, 2021
Lead Product(s) : OCS-02
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Oculis
Deal Size : Undisclosed
Deal Type : Partnership
Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02
Details : OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.
Brand Name : OCS-02
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 06, 2021
Details:
Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV, which includes RP-L102 genetically modified with a lentiviral vector.
Lead Product(s): RP-L102
Therapeutic Area: Rare Diseases and Disorders Brand Name: RP-L102
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Rocket Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 20, 2021
Lead Product(s) : RP-L102
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Rocket Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
AGC Biologics Expands Partnership with Rocket Pharmaceuticals
Details : Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV, which includes RP-L102 genetically modified with a lentiviral...
Brand Name : RP-L102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 20, 2021
Services
Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Biologic Drugs
Sub Category : DNA / RNA
Pharma Service : Drug Product Manufacturing
ABOUT THIS PAGE
AGC Biologics is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Matrix-C bulk with JDMF offered by AGC Biologics
Find a price of Matrix-A bulk with JDMF offered by AGC Biologics
LOOKING FOR A SUPPLIER?